Benjamin Esparaz

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial”.

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

Journal of Clinical Oncology(2025)10.1200/jco-24-01710

N/A

0.458DataRank · unranked

9 citations

Katherine A. Guthrie, Benjamin Tan, Crystal S. Denlinger, Marwan Fakih, Michael J. Overman +15 more

Blood Clock Correlation Distance (BloodCCD) as a novel marker to detect circadian rhythm disruption in cancer survivors with insomnia

BJC Reports(2025)10.1038/s44276-025-00176-9

N/A

0.168DataRank · unranked

2 citations

Po‐Ju Lin, Lindsey Jean Mattick, Elliot Outland, Javier Bautista, Chin-Shang Li +15 more

A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013

Journal of Patient-Reported Outcomes(2020)10.1186/s41687-020-00220-x

N/A

0DataRank · unranked

5 citations

Joseph M. Unger, James L. Wade, Lynne I. Wagner, Mario E. Lacouture, Keisha C. Humphries +15 more

Association of changes of pro-inflammatory markers with physical function in women with breast cancer receiving chemotherapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.562

N/A

0DataRank · unranked

2 citations

Elizabeth Belcher, Po‐Ju Lin, Amber S. Kleckner, Sindhuja Kadambi, Kah Poh Loh +8 more

A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.140

N/A

0DataRank · unranked

7 citations

Katherine A. Guthrie, Scott Kopetz, Benjamin Tan, Crystal S. Denlinger, Marwan Fakih +15 more